Published in Obesity and Diabetes Week, May 3rd, 2004
"The availability of effective surgical treatments coupled with the near total lack of effective pharmacotherapy for diabetic retinopathy has kept drug-treated rates - and thus pharmaceutical sales for this disease - exceedingly low," said Kat Neumeyer, analyst at Decision Resources. "However, the launch of novel drug therapies will prompt dramatic increases in the drug- treated population, which will nearly quadruple in the major pharmaceutical markets (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom)."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week